Rejected from Circulation Research? Where to Submit Next

Circulation Research rejections split into route-now and fix-first cases. Route-now means the manuscript is valid cardiovascular science but aimed at the wrong cardiovascular audience. Fix-first means the next journal will see the same mechanism or evidence problem.

The highest-leverage question is simple: did Circulation Research reject the venue fit, or did it reject the mechanistic evidence?

This route map prevents the common mistake after Circulation Research rejection: moving by prestige signal instead of deciding whether the paper is basic mechanism, translational biology, clinical cardiology, vascular biology, electrophysiology, heart failure, hypertension, stroke, or specialty cardiovascular science.

In our pre-submission review work on Circulation Research submissions, the strongest predictor is whether the figure sequence closes a cardiovascular mechanism. We inspect the title, abstract, first figure, perturbation experiment, rescue evidence, in vivo physiology, human or clinical relevance, statistical design, and supplement before worrying about citation style.

Association before mechanism. The manuscript shows that a gene, protein, metabolite, immune population, imaging feature, or biomarker changes in cardiovascular disease, but it does not explain the causal pathway from molecule to function. Circulation Research can reject that quickly because the paper still asks the editor to infer mechanism.

One model system carrying a broad claim. A single mouse model, one cell line, one omics dataset, or one patient cohort may be enough for a narrower journal, but it rarely supports a broad cardiovascular-biology claim at this level. A stronger resubmission usually needs orthogonal validation, rescue, perturbation, or human-tissue relevance.

Clinical paper wearing mechanism language. Some papers belong in Circulation, JACC, EHJ, or an AHA clinical specialty journal because the real contribution is clinical outcome, risk prediction, imaging utility, procedure, or practice relevance. Adding a mechanistic paragraph does not make the manuscript a Circulation Research paper.

Incomplete reporting for cardiovascular biology. Animal studies without sex, age, randomization, blinding, strain, sample-size, or ARRIVE discipline; qPCR without MIQE discipline; omics without repository and analysis-code clarity; and imaging or physiology studies without protocol detail all weaken the package before the science is fully evaluated.

We see the strongest recoveries when authors stop treating the rejection as only a prestige problem. If the mechanism is real but narrow, Cardiovascular Research, Basic Research in Cardiology, or a specialty journal can be a better reader. If the patient-facing result is the true contribution, Circulation, JACC, EHJ, or an AHA clinical title may be cleaner. If the missing experiment is obvious, the right move is to run it before resubmission.

Our analysis of Circulation Research submission packages treats the rejection letter as a routing artifact, not just a verdict. The useful question is which manuscript component failed first: the first figure, the perturbation experiment, the rescue design, the functional endpoint, the human-relevance bridge, the statistics, or the target-journal premise. Once that component is named, the next journal choice becomes much less speculative.

Cardiovascular Research is often the cleanest next target when the manuscript remains mechanistic cardiovascular science but does not quite fit the Circulation Research flagship slot.

Choose Cardiovascular Research when:

• the mechanism is cardiovascular and experimentally grounded
• the paper has enough depth for cardiovascular scientists but a narrower significance claim
• the abstract can state the pathway, model, and functional consequence without overclaiming
• the figures show more than descriptive association
• the paper is not primarily a clinical-practice or outcomes manuscript

Pause before choosing it when:

• Circulation Research rejected the manuscript for missing causal experiments
• the biology rests on one model with no orthogonal validation
• the paper is mainly clinical outcomes, imaging utility, or risk prediction
• the cardiovascular relevance is indirect

The rewrite should make the mechanism proportionate rather than trying to preserve the rejected Circulation Research ambition.

If the rejection says the paper is not the right basic-science fit, route by the manuscript's actual center.

The cover letter should change accordingly. Do not present a clinical cohort paper as a basic-mechanism paper just because Circulation Research was the first target.

The next cover letter should not sound like a lightly edited Circulation Research letter.

For Cardiovascular Research:

This manuscript explains a cardiovascular mechanism with experimental support and a proportionate claim for cardiovascular-science readers.

For JACC: Basic to Translational Science:

This manuscript connects mechanistic cardiovascular biology to a translational question, with evidence that bridges experimental findings and human disease relevance.

For ATVB:

This manuscript centers on vascular biology, thrombosis, atherosclerosis, inflammation, lipid biology, or endothelial function, with mechanism and functional consequence aligned to the ATVB readership.

For Circulation:

This manuscript addresses a clinical cardiovascular question with practice-facing consequence, patient-level evidence, and a clear explanation of what clinicians should understand or do differently.

For a specialty cardiovascular journal:

This manuscript is best evaluated by specialists in the disease or method lane because the contribution is rigorous but narrower than a broad cardiovascular-biology flagship article.

If the paragraph sounds dishonest, the target is wrong or the manuscript needs more work.

Run this checklist before uploading the next version:

• [ ] The abstract states a cardiovascular mechanism, clinical question, or specialty endpoint honestly.
• [ ] The first figure does not stop at descriptive disease-state difference.
• [ ] Perturbation, rescue, loss/gain-of-function, or functional validation matches the claim.
• [ ] The evidence is not dependent on one model system unless the claim is appropriately narrow.
• [ ] Human, tissue, animal, cell, omics, or physiology evidence is used proportionately.
• [ ] AHA reporting requirements, data availability, statistical design, and supplement are complete.
• [ ] The cover letter is written for the next journal's actual reader, not for Circulation Research.
• [ ] Any AHA transfer option is evaluated as a fit suggestion, not an automatic path.

Before submitting elsewhere, run a Circulation Research resubmission readiness check to catch the mechanism, validation, and cardiovascular-fit defects that often follow rejected manuscripts to the next journal.